Literature DB >> 26336183

Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.

Ahmed Al-sharefi1, Rudy Bilous2.   

Abstract

We describe a case of a 35-year-old woman who presented with bilateral leg weakness and encephalopathy while on long-term valproate therapy. She was diagnosed with valproate-induced encephalopathy due to carnitine deficiency. Clinical improvement occurred with oral carnitine supplementation. Our case report highlights the importance of considering carnitine deficiency in patients presenting with unexplained neurological signs while on long-term valproate treatment. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26336183      PMCID: PMC4567754          DOI: 10.1136/bcr-2015-210727

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.

Authors:  Amit Chopra; Bhanu Prakash Kolla; Meghna P Mansukhani; Pamela Netzel; Mark A Frye
Journal:  Gen Hosp Psychiatry       Date:  2012-02-02       Impact factor: 3.238

Review 2.  Hyperammonemia due to valproic acid in the psychiatric setting.

Authors:  Russell B Carr; Kerrie Shrewsbury
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

3.  Carnitine for valproic acid-induced hyperammonemia.

Authors:  W N Raby
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

4.  The effect of carnitine supplementation in valproate-induced hyperammonaemia.

Authors:  H Böhles; A C Sewell; D Wenzel
Journal:  Acta Paediatr       Date:  1996-04       Impact factor: 2.299

5.  Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients.

Authors:  Miroslav Cuturic; Ruth K Abramson; Robert R Moran; James W Hardin; Alicia V Hall
Journal:  World J Biol Psychiatry       Date:  2010-06-29       Impact factor: 4.132

6.  Valproate-induced hyperacute hyperammonemic coma in a patient with hypocarnitinemia.

Authors:  Aijaz Sofi; Nabeel A Herial; Imran I Ali
Journal:  Am J Ther       Date:  2013 Nov-Dec       Impact factor: 2.688

7.  Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.

Authors:  F Barrueto; J B Hack
Journal:  Acad Emerg Med       Date:  2001-10       Impact factor: 3.451

8.  Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review.

Authors:  Miroslav Cuturic; Ruth K Abramson; Robert R Moran; James W Hardin
Journal:  J Psychiatr Pract       Date:  2010-01       Impact factor: 1.325

9.  Hyperammonemia induced by interaction of valproate and quetiapine.

Authors:  Athar Halaby; Ramzi Haddad; Wadih J Naja
Journal:  Curr Drug Saf       Date:  2013-09

Review 10.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

View more
  3 in total

Review 1.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

2.  L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.

Authors:  Emily R Vasiljevski; Joshua Burns; Paula Bray; Gabrielle Donlevy; Anita J Mudge; Kristi J Jones; Matthew A Summers; Andrew Biggin; Craig F Munns; Marnee J McKay; Jennifer N Baldwin; David G Little; Aaron Schindeler
Journal:  Am J Med Genet A       Date:  2021-06-21       Impact factor: 2.578

3.  Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1).

Authors:  Emily R Vasiljevski; Peter J Houweling; Thusitha Rupasinghe; Tarneet Kaur; Matthew A Summers; Ute Roessner; David G Little; Aaron Schindeler
Journal:  PLoS One       Date:  2020-08-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.